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Background. Mild to moderate adverse events (AEs) are common after treatment of lymphatic filariasis (LF) and pose a major
challenge for the global LF elimination program. We studied changes in cytokine levels and filarial worm components in plasma of
subjects with and without AEs following treatment of LF.
Methods. Participants (n = 24) were hospitalized and monitored for AEs following treatment. Cytokines (27), filarial DNA,
circulating filarial antigen (CFA), and immune complexes were measured in plasma samples collected before and after treatment.
Results. Levels for 16 cytokines increased after treatment in individuals with moderate AEs compared to individuals with no
and/or mild AEs. These included 3 major proinflammatory cytokines (interleukin 6, tumor necrosis factor α, and interleukin 1β).
Eotaxin-1 levels were elevated at baseline in individuals who developed moderate AEs after treatment; thus, eotaxin-1 is a potential
biomarker for AE risk. CFA and filarial DNA levels increased more in individuals with moderate AEs after treatment than in people
with no/mild AEs.
Conclusions. Increases in cytokine, filarial DNA, and CFA levels were associated with development of AEs following treatment
of LF. Improved understanding of the pathogenesis of AEs may lead to improved methods for their prevention or management that
could increase compliance in elimination programs.
Keywords. lymphatic filariasis; therapy; adverse events; cytokines; circulating filarial antigenemia.
Lymphatic filariasis (LF) is a neglected tropical disease that
is caused by the nematode parasites Wuchereria bancrofti,
Brugia malayi, and Brugia timori. Adult worms release firststage larvae (microfilariae [Mf]) into the blood, and these
are ingested by mosquitoes. The parasites develop to become
infective third-stage larvae that can initiate new infections
when they are transmitted to humans by mosquitoes. The
worms and the host’s inflammatory responses can lead to
severe morbidity with lymphedema, hydrocele, and elephantiasis [1].
The World Health Organization (WHO) launched the Global
Program to Eliminate LF (GPELF) in the year 2000 with the goal
of eliminating LF as a public health problem by 2020. The primary tool used by GPELF is annual mass drug administration
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(MDA), and some 500 million people are treated each year [2].
The medications used—namely, albendazole (ALB), ivermectin
(IVM), and diethylcarbamazine (DEC)—have well-established
safety profiles, and serious adverse events (AEs) related to treatment are very rare. However, mild to moderate AEs such as fever
and headache are common. High MDA compliance is important
for LF elimination programs [3]. The fear of AEs in communities receiving MDA reduces compliance [4, 5]. Understanding
the pathogenesis of AEs is even more urgent at this time, because
recent studies have shown that a single dose of all 3 LF MDA
drugs (IVM, DEC and ALB, sometimes called “IDA”) is more
effective for clearing Mf than the current 2-drug MDA regimens
[6] (authors’ unpublished observations). This increased efficacy
may be associated with increased AE rates in infected individuals.
The pathogenesis of AEs after treatment of LF is poorly
understood. Host immune responses and parasite death are
believed to be involved, because posttreatment AE rates are
much higher in infected individuals, and because AE rates are
correlated with blood Mf counts [7]. AEs are probably related
to release of parasite antigens and/or Wolbachia (an intracellular alpha proteobacteria found in LF-causing filarial worms).
Wolbachia-derived molecules may interact directly with the
innate immune system through ligands such as Toll-like receptors (TLRs) to activate immune cells to release cytokines [8–13].
Few studies have looked at changes in cytokines associated with
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Changes in Cytokine, Filarial Antigen, and DNA Levels
Associated With Adverse Events Following Treatment of
Lymphatic Filariasis

METHODS
Study Design

Plasma samples used for this study were obtained during a pharmacokinetic trial conducted in Papua New Guinea in 2013 [6].
Twenty-four W. bancrofti–infected individuals were randomized
to 1 of 2 treatment arms: the standard LF MDA regimen for Papua
New Guinea (ALB and DEC) or the new IDA triple therapy regimen. The AE assessment protocol was described in a previous
publication [6]. In brief, objective AEs were assessed (vital signs
and a brief physical examination) for all study participants at 0,
4, 8, 12, 24, 48, and 72 hours posttreatment in a hospital setting.
Subjective AEs were assessed at the same times by asking the participants open-ended questions about symptoms that developed
after treatment. All participants were followed as outpatients and
examined on day 7. Nineteen of 24 participants (79%) developed
at least 1 AE, and 7 of these individuals had fever >38°C. Blood
was collected immediately before treatment and at 11 time-points
after treatment (1–72 hours). Notable in this study was the high
Mf levels (geometric mean, 1679 [range, 133–13 776] Mf/mL).
Plasma samples were stored and shipped at –80°C. Informed consent was obtained from all participants as previously described [6].
Adverse Events Classification

AEs were scored as none, mild, or moderate. Those with moderate AEs (n = 7) had at least 1 new symptom plus objectively
measured fever (a temperature of ≥38°C) within 72 hours after
treatment. Individuals with subjective or objective AEs without
fever were considered to have mild AEs (n = 12). Individuals
with no objective or subjective symptoms were considered to
have no AEs (n = 5).
Cytokine Assay

Twenty-seven cytokines were measured using a MAGPIX system
with the Bio-Plex Human 27-Plex Cytokine Panel and Bio-Plex
Cytokine Reagent Kit (Bio-Rad, Hercules, California). Plasma
samples were thawed and centrifuged before testing. A preliminary study tested samples from all 12 time-points (pretreatment
and 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours posttreatment)
for 7 participants. Since there were no changes in cytokine levels

during the first 6 hours, only 7 time points (pretreatment and 8,
12, 24, 36, 48, and 72 hours posttreatment) were tested for the
remaining 17 study participants. All samples were tested in duplicate, and all samples from the same individual were run on the
same plate. The cytokine assay panel included IL-1β, IL-1Ra, IL-2,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15,
IL-17, basic fibroblast growth factor (FGF), eotaxin-1, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage
colony-stimulating factor (GM-CSF), interferon gamma (IFN-γ),
interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein
(MIP) 1β and 1α, platelet-derived growth factor BB (PDGF-BB),
regulated on activation, normal T cell expressed and secreted
(RANTES), TNF-α, and vascular endothelial growth factor
(VEGF). Standard curves were calculated using the manufacturer’s software, and our analysis considered mean concentrations
(picograms per milliliter) from 2 duplicate wells. Mean levels
for all 27 cytokines were calculated for each AE group at each
time-point. Kruskal–Wallis H tests were used to compare absolute cytokine levels between the 3 AE groups at each time-point.
Wilcoxon signed-rank tests were used to compare posttreatment
levels to baseline levels within AE groups for each time-point.
After evaluation of the data, 3 outliers with extremely elevated
levels at baseline were excluded from the analysis.
Circulating Filarial Antigen

A direct sandwich enzyme immunoassay was performed as previously described [19, 20]. Plasma samples were available for
21 of the 24 individuals for this test (6 moderate, 10 mild, and
5 no AEs), and samples from 5 time-points were tested (pretreatment and 6, 12, 24, and 48 hours posttreatment). All samples from individual participants were tested in duplicate on the
same plate. The mean circulating filarial antigen (CFA) levels
were calculated for each AE group at each time-point. Kruskal–
Wallis H tests were used to compare the absolute CFA levels
between the 3 AE groups at each time-point. Wilcoxon signedrank tests were used to compare posttreatment CFA levels at
each time-point to baseline levels within the AE groups.
Detection of Filarial DNA by Quantitative Polymerase Chain Reaction

DNA was extracted from 100 µL of plasma using the E.Z.N.A.
Tissue DNA Kit (Omega Bio-tek) using the manufacturer’s
protocol. The quantitative polymerase chain reaction (qPCR)
assay was a TaqMan probe-based assay, and the target was the
“long DNA repeat” of W. bancrofti (GenBank accession number
AY297458). We used previously published primers and probes
[21] purchased from Integrated DNA Technologies. Real-time
PCR reactions were performed with 10 μL of TaqMan master
mix (Applied Biosystems) plus 450 nmol/L of primers, 125 nmol/L probe, and 2 μL DNA with a final volume of 20 μL. Thermal
cycling was performed with a QuantStudio 7-Plex Real-Time
PCR System (Applied Biosystems). PCR reactions were carried
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AEs following LF treatment. One study documented increases
in interleukin (IL) 6 and tumor necrosis factor alpha (TNF-α)
after treatment in 5 men with AEs [14]. Another study reported
that AEs were associated with increased levels of IL-6, lipopolysaccharide binding protein (LBP), IL-10, and soluble TNF
receptor [15]. Other studies suggested that AEs may be related
to circulating immune complexes (CICs) that form when filarial antigens are released by dying parasites [16, 17]. CICs from
plasma of LF-infected individuals have been shown to be proinflammatory when added to granulocytes [18]. A recent clinical trial provided us with the opportunity to use 21st-century
methods to revisit the issue of AE pathogenesis.

Immune Complex Assay

In this assay, CICs were incubated with human C1q (part of
the first component in the classical complement pathway) that
was immobilized on microtiter plates. C1q was purchased from
Sigma-Aldrich. Nunc Immulon 2HB flat-bottom 96-well plates
(Thermo Scientific) were coated with 50 µL of 0.01 mg/mL C1q
in 1× phosphate-buffered saline (PBS) pH7.4 and incubated at
4°C overnight. Plates were washed and blocked for 1 hour at
room temperature. After washing, 50 µL sample plasma or standard (diluted 1:60 in PBS with 0.5% casein, 0.5% Tween-20) was
added to each well, and the plates were incubated at room temperature for 1 hour. Aggregated human γ-globulin (AHG) was
used as the positive control and standard. Alkaline phosphatase-conjugated goat antihuman immunoglobulin G was used at
a dilution of 1:1000, and plates were incubated for 1 hour at 37°C.

The plates were developed with alkaline phosphatase substrate
(pNPP disodium salt hexahydrate) and read at 405 nm. Plasma
was available from 22 of the 24 individuals for this assay (7 moderate, 10 mild, and 5 no AEs), and 7 time-points were selected
(pretreatment and 8, 12, 24, 36, 48, and 72 hours posttreatment).
Samples were run in duplicate and all samples from individual
participants were run on the same plate. Each plate contained 2
negative controls (plasma samples from healthy North American
control subjects and deionized water). Values were expressed as
nanograms per milliliter of AHG, and mean CIC values were calculated for each AE group at each time-point. Kruskal–Wallis H
tests were used to compare absolute CIC levels between the 3 AE
groups at each time-point. Wilcoxon signed-rank tests were used
to compare posttreatment CIC levels at each time-point to baseline levels within each AE group.
RESULTS
Cytokine Levels

Three of the 24 individuals (all in the mild AE group) had extremely elevated cytokine levels at baseline, and they were
excluded from the analysis. These 3 individuals had outlier levels for 9, 12, and 14 of the 27 measured cytokines respectively,
at baseline. These high baseline cytokine levels were unrelated
to treatment and their inclusion would have distorted the data,
because the aim of the study was to investigate the change in
cytokines posttreatment.
Changes in cytokine levels after treatment were significantly
different in persons with moderate AEs compared to those in
persons with no and/or mild AEs for 22 of the 27 cytokines

Table 1. Changes in Cytokines at Different Times After Treatment in Persons Who Developed Moderate Adverse Events (AEs) After Treatment of Filariasis
Compared to Those With No or mild AEs
Hours post
treatment

IL-1β

IL-1Ra

8

++

12

IL-2

IL-4

IL-6

++

+

++

++

++

+

++

+

+

IL-7

0

IL-10

IL-12

IL-13

++

+

+

++

+

+

+

24
36

IL-8

+

-

+

+
-

+

+

+

+

++

++

+

48

IL-15

+

-

72
Hours post
treatment

IL-17A

G-CSF

IP-10

MCP-1

MIP-1α

++

+

+

++

++

12

++

++

++

++

++

24

++

++
++

0
8

Eotaxin-1

PDGF-BB

MIP-1β

++
+

RANTES

TNF-α

VEGF

--

36

+

48

++

++

72

+

+

+

++

-

++

-

+

+

-

+

+

+

++
+
+
+

+

These differences were due to significant increases (represented with plus signs) in cytokine levels in the moderate AE group compared to the no and/or mild AE groups (Kruskal-Wallis
analysis followed by post-hoc tests to determine which AE groups were statistically different). IL-2, IL-15 and RANTES were exceptions as these cytokines were decreased (represented with
minus signs) before and/or after treatment in the moderate AE group. Significance (by the Kruskal-Wallis H Test): + or - corresponds to P < .05; ++ or - - corresponds to P < .01.
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out for 40 cycles, and cycle threshold (Ct) values were determined using the manufacturer’s software. Plasma samples were
available for 21 of the 24 individuals for this assay (7 moderate,
9 mild, and 5 no AEs), and 7 time-points were selected (pretreatment and 8, 12, 24, 36, 48, and 72 hours posttreatment).
Samples were run in duplicate, and all samples from individual participants were tested on the same plate. Each plate contained a positive control (DNA extracted from W. bancrofti Mf),
and 2 negative controls (DNA extracted from plasma samples
from healthy North American control subjects and deionized
water). Delta Ct values (baseline Ct value minus posttreatment
Ct value) were calculated at each time-point for each individual,
and 1-way analysis of variance analysis was used to compare the
∆Ct values between the 3 AE groups at each time-point.
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Figure 1. Mean cytokine levels (± standard error [SE]) in the 3 adverse event (AE) groups over time. Interleukin 6 (IL-6) (A), interleukin 10 (IL-10) (B), monocyte chemoattractant protein 1 (MCP-1) (C), and macrophage inflammatory protein 1β (MIP-1β) (D) increased posttreatment in the moderate AE group, whereas there were no significant
changes in the no or mild AE groups. Significance (Kruskal–Wallis H test): * P < .05; **P < .01.

tested (Table 1) (Kruskal–Wallis analysis followed by post hoc
tests to determine which AE groups were significantly different). Most of these cytokines (IL-1β, IL-1Ra, IL-4, IL-6, IL-7,
IL-10, IL-12, IL-17, G-CSF, IP-10, MCP-1, MIP-1α, PDGF-BB,
MIP-1β, TNF-α, and VEGF) increased significantly more in the
moderate AE group after treatment compared to the no and/
or mild AE groups. IL-6, IL-10, MCP-1 and MIP-1β had the
most dramatic posttreatment increases in the moderate AE
group (Figure 1). Several cytokines (IL-8, IL-13, and eotaxin-1)
were significantly higher at baseline in persons who developed
moderate AEs. Eotaxin-1 was greatly increased pretreatment in
6 out of the 7 individuals who later developed moderate AEs
(Figure 2). Baseline eotaxin-1 levels were not correlated with
baseline Mf counts. The finding that some cytokines were higher
at baseline in individuals who would go on to develop AEs was
surprising, and we decided to redo the analysis including the
3 excluded individuals. There was still a significant difference
in baseline eotaxin-1 and IL-8 levels between individuals with

moderate AEs compared with individuals with no and/or mild
AEs. However, the difference in IL-13 at baseline disappeared
when the outliers were included.
Values for several cytokines were lower at baseline (RANTES)
or decreased significantly posttreatment (IL-2 and IL-15) in
people who developed moderate AEs compared with people
with no and/or mild AEs. Five cytokines (IL-5, IL-9, basic FGF,
GM-CSF, and IFN- γ) did not differ by AE group at any timepoint; however, IL-5 did increase posttreatment as previously
described [22, 23]. We did not correct for multiple comparisons, so additional data would be needed to confirm our findings. However, the differences in cytokine levels were dramatic
between the AE groups, and they persisted over time making
the results more credible. Based on the standard significance
level of .05, approximately 3 differences would be expected to
be significant by chance for 54 tests (27 cytokines measured at
2 time-points). We found 28 significant differences in cytokines
levels at 12 and 24 hours posttreatment.
Adverse Events After Treatment of LF • JID 2018:217 (15 January) • 283
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Figure 2. Mean eotaxin-1 levels (± standard error) for all 3 adverse event (AE) groups over time. Eotaxin-1 levels were significantly higher at all time-points in the moderate
AE group compared with the no and/or mild AE groups. Significance (Kruskal–Wallis H test): *P < .05; **P < .01.

CFA Levels and Mf Counts

CFA is known to circulate in the blood of LF-infected individuals, and this antigen is used as a diagnostic marker. The
detection limit of the CFA enzyme immunoassay assay is
6.3 ng/mL. CFA was detected in all samples from all study
subjects. Baseline CFA levels were positively correlated with
baseline Mf counts (Spearman ρ = 0.66, P = .001), and absolute CFA levels were significantly higher at baseline in the
individuals who later developed moderate AEs. CFA levels
were significantly higher in the moderate AE group compared to the no/mild AE groups at all time-points (Figure 3).
CFA levels increased in all groups after treatment, but the
difference was only significant at the 48-hour time-point
(P = .048 by Wilcoxon signed-rank test) compared to the
baseline level in the moderate AE group. There was no difference in absolute CFA levels between the 2 treatment arms
at any time-point.
Baseline Mf counts were higher in individuals who developed
moderate AEs (geometric mean, 4491 Mf/mL vs 1111 Mf/mL in
the mild AE group and 1351 Mf/mL in the no AEs group), and
this difference was significant (P = .017 by the Kruskal–Wallis
test).
Filarial DNA Levels

Thirty-three percent of participants had detectable filarial DNA in plasma collected before treatment. There was no
correlation between pretreatment Ct values and baseline Mf
counts (Spearman ρ = –0.1). Filarial DNA was detected in
plasma of all subjects at 8 hours posttreatment. Also, filarial
DNA levels increased (Ct values decreased) after treatment
in persons with filarial DNA detected at baseline. DNA levels
284 • JID 2018:217 (15 January) • Andersen et al

quickly increased for the first 12–24 hours after treatment,
after which they start to decrease. However, filarial DNA was
still detectable in plasma in 95% of individuals 72 hours posttreatment. There was a statistically significant difference in
∆Ct values between the 3 AE groups at 12 and 24 hours posttreatment, and this difference was due to significantly higher
∆Ct values (larger increase in DNA levels) in the moderate AE
group compared to the mild AE group (Figure 4). A similar
trend was observed between the moderate and no AE groups,
but the difference was not statistically significant due to the
small number of individuals in the no AE group (n = 5). There
were no significant differences in filarial DNA levels in plasma
by treatment arm at any time-point.
CIC Levels

CIC were detected in all samples, and the range at baseline was
108–1312 ng AHG equivalent/mL (median, 417 ng). Baseline
CIC levels were positively correlated with Mf counts (Spearman
ρ = 0.68, P = .006). There was no difference in absolute CIC
levels between the AE groups at any time-point (Supplementary
Table 1). CIC levels were relatively stable after treatment, and
there were no consistent patterns as differences included both
increases and decreases.
DISCUSSION

The aim of this study was to determine the role of host cytokines,
and filarial components released by parasites after treatment, in
the development of AEs in LF-infected individuals. This is the
most detailed study to date of cytokine responses that occur in
persons with AEs after treatment of LF. We identified 22 cytokines that were differentially regulated posttreatment between
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Figure 3. Mean W. bancrofti (Wb) circulating filarial antigen (CFA) levels (± standard error) for each adverse event (AE) group over time. CFA levels were significantly
higher in the moderate AE group than in the no and mild AE groups. Significance
(Kruskal–Wallis H test): *P < .05; **P < .01. CFA levels were significantly higher at
48 hours posttreatment compared with baseline in the moderate AE group (P = .048
by Wilcoxon signed-rank test).

the 3 AE groups. The majority of these cytokines increased
more posttreatment in persons who developed moderate AEs.
Our data are consistent with previously published results such
as increases in IL-6, TNF-α, and IL-10 posttreatment in people with AEs [14, 15]. However, we also found that many other
cytokines increased in participants with moderate AEs.
Plasma levels of filarial DNA and CFA both increased after
treatment, and posttreatment increases in CFA were much more
dramatic in people who developed moderate AEs than in those
with no/mild AEs. Treatment with ALB/DEC and IVM/DEC/
ALB resulted in similar changes in CFA and filarial DNA levels
after treatment, suggesting that the 2 treatments have similar
activity against Mf and adult filarial worms in the first days after
treatment. CFA levels increased slightly later after treatment
than filarial DNA, but the CFA increases persisted for a longer
time. This result is consistent with prior reports of increased
CFA levels 5–7 days posttreatment [24, 25]. Taken together, our
results suggest that cytokines, filarial DNA, and CFA all may be
involved in the pathogenesis of AEs. It is likely that the cytokine responses are triggered by molecules that are released from
dying parasites. However, it is unclear whether cytokine release
is triggered by phagocytosis of parasite debris or by direct interaction of parasite molecules with ligands on the surface of
host cells. Compared to filarial DNA and CFA levels, CIC levels
were stable after treatment, and there was no difference in CIC
levels between the AE groups at any time-point. These results
suggest that CIC may not be involved in the pathogenesis of
moderate AEs.
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Figure 4. Filarial DNA levels in plasma (expressed as ∆ cycle threshold [Ct] ±
standard error) after treatment by adverse event (AE) group. Ct values decreased
after treatment in all 3 AE groups, signifying an increase in filarial DNA levels in
plasma. Mean ∆Ct values were significantly greater in the moderate AE group compared with the mild AE group at 12 (P = .025) and 24 (P = .020) hours posttreatment
(by analysis of variance). *P < .05.

Cytokine changes have been extensively studied in patients
with septicemia or after exposure to endotoxin with sequential
increases in TNF-α, IL-1β, IL-6, IL-1Ra, and IL-10 [26]. The
cytokine pattern in this study was somewhat similar in that
TNF-α was the first to increase with a peak at 8 hours posttreatment. IL-6 had the largest increase (a 13-fold increase in
the moderate AE group) with a peak at 12 hours. IL-10, which
increases later after endotoxin exposure, was not delayed in
this study; it rose by 8 hours and peaked at 12 hours. Increases
in proinflammatory cytokines may be stimulated by release
of Wolbachia from dying filarial worms, but additional studies will have to be conducted to test this hypothesis. Dramatic
increases in MCP-1 and MIP-1β/1α in persons with moderate
AEs suggest that monocytes and/or macrophages are involved
in the pathogenesis of AEs. Both of these cytokines are released
by macrophages after endotoxin exposure [27], so this finding
is consistent with the Wolbachia release hypothesis. Although
Wolbachia do not contain lipopolysaccharide, they do contain
endotoxin-like lipoproteins that interact with cellular ligands
TLR2 and TLR6 [9, 11, 13].
Several baseline characteristics are known to be correlated
with development of AEs after treatment of LF. For example,
high Mf counts are a known risk factor [7], and our study confirmed that this is the case. High CFA levels have not been
previously identified as a risk factor for AEs, perhaps because
antigen levels were not measured. However, the association is
not surprising, because CFA levels are positively correlated with
Mf counts. The finding that participants with elevated levels of
Adverse Events After Treatment of LF • JID 2018:217 (15 January) • 285
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Supplementary Data

Supplementary materials are available at The Journal of Infectious
Diseases online. Consisting of data provided by the authors to
benefit the reader, the posted materials are not copyedited and
are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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